24 September 2018 - Verastem today announced that the U.S. FDA has approved Copiktra, an oral inhibitor of phosphoinositide 3-kinase, and the first approved dual inhibitor of PI3K-delta and PI3K-gamma. 

Copiktra is approved for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukaemia/small lymphocytic lymphoma after at least two prior therapies.

Copiktra also received accelerated approval for the treatment of adult patients with relapsed or refractory follicular lymphoma after at least two prior systemic therapies. The indication in follicular lymphoma is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Read Verastem press release